An Early Negative Result for Tau Immunotherapy

Immunotherapy is a promising approach for the treatment of Alzheimer's disease, in which immune cells are directed to attack amyloid aggregates or precursor proteins associated with the condition. More pertinently, this field of research could produce a successful and mature technology platform for targeting all forms of amyloid, and possibly other types of metabolic waste, that should be cleared from the body in order to remove their contributions to degenerative aging. Unfortunately progress is slow and challenging: Alzheimer's is complex, the immune system is complex, and both are incompletely understood. There continue to be many more failures than successes in the process of development.

One more recent line of work is to focus on tau aggregates rather than amyloid. There is evidence to suggest that these neurofibillary tangles are also significant in the progression of Alzheimer's disease, but again understanding of the mechanisms involved is at this point sketchy. From an engineering point of view forging ahead to build a removal mechanism in advance of full knowledge is a good approach, if it can be done given the present state of knowledge. It stands a reasonable chance of cutting straight to a viable treatment even in absence of greater knowledge, or at least shedding more light on the situation if it clears tau and yet still fails to improve the outcome for a treated individual. In this case researchers encounter a fairly typical result in this work, which is that they are floundering on unanticipated complexity, but learning as they go:

The amyloid β (Aβ)-protein and microtubule-associated protein, tau, are the major components of the amyloid plaques and neurofibrillary tangles that typify Alzheimer's disease (AD) pathology. As such both Aβ and tau have long been proposed as therapeutic targets. Immunotherapy, particularly targeting Aβ, is currently the most advanced clinical strategy for treating AD. However, several Aβ-directed clinical trials have failed, and there is concern that targeting this protein may not be useful. In contrast, there is a growing optimism that tau immunotherapy may prove more efficacious.

Here, for the first time, we studied the effects of chronic administration of an anti-tau monoclonal antibody (5E2) in amyloid precursor protein transgenic mice. For our animal model, we chose the J20 mouse line because prior studies had shown that the cognitive deficits in these mice require expression of tau. Despite the fact that 5E2 was present and active in the brains of immunized mice and that this antibody appeared to engage with extracellular tau, 5E2-treatment did not recover age-dependent spatial reference memory deficits. These results indicate that the memory impairment evident in J20 mice is unlikely to be mediated by a form of extracellular tau recognized by 5E2.

In addition to the lack of positive effect of anti-tau immunotherapy, we also documented a significant increase in mortality among J20 mice that received 5E2. Because both the J20 mice used here and tau transgenic mice used in prior tau immunotherapy trials are imperfect models of AD our results recommend extensive preclinical testing of anti-tau antibody-based therapies using multiple mouse models and a variety of different anti-tau antibodies.



This is a negative result in the narrow sense, but this was not any kind of failure of the "damage-repair" approach advocated by SENS Research Foundation. The antibody they used here (5E2) binds nonspecifically to native and phosphorylated tau as well as to neurofibrillary tangles (NFT). But native tau and most phospho-tau species are physiological proteins, and clearance of them with an antibody or any other approach is exactly the kind of "messing with metabolism" (typified by medicine by risk-factor management and by the pursuit of CR mimetics and similar approaches to intervention in aging) that we are working to move the field beyond.

Only aggregated tau species — oligomers, NFT and aberrant tau cleavage products — are legitimate targets for rejuvenation biotechnologies. And as reviewed in several posts on this subject, progress in developing vaccines targeting aberrant tau is promising and ongoing.

Immunotherapeutic clearance of the damaged proteins driving brain aging is a rapidly-maturing field. In the last year or so, we have witnessed the first human trial of a vaccinate against α-synuclein aggregates graduate into Phase IIb testing and be joined by a second. Meanwhile, regulators, industry, and advocates came together in a series of groundbreaking summits that led FDA to authorize innovative new clinical trial designs for testing beta-amyloid immunotherapies that will allow these vaccines to prove what they can do, and (we advocate and anticipate) serve as a template for other trials of rejuvenation biotechnology.

With so much activity in the paradigm and extensive preclinical work established, it's only a matter of time before a strong aberrant tau vaccine candidate enters into human testing — and ultimately helps to rejuvenate the aging brain and put an end to degenerative brain aging.

Posted by: Michael at January 27th, 2015 6:25 PM

Post a comment; thoughtful, considered opinions are valued. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.